Drug Profile
EGT 022
Alternative Names: EG 22; EG-Decorin; EG-Mirotin; EGT022; HU-005Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator EyeGene
- Developer EyeGene; Huons
- Class Cardiovascular therapies; Eye disorder therapies; Membrane proteins; Peptides; Recombinant proteins; Vascular disorder therapies
- Mechanism of Action Angiogenesis inducing agents; Platelet derived growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Diabetic foot ulcer; Diabetic retinopathy; Pressure ulcer
- No development reported Retinopathy of prematurity
Most Recent Events
- 28 Sep 2021 No development reported - Phase-II for Diabetic retinopathy in European Union (IM) (EyeGene pipeline, September 2021)
- 28 Sep 2021 No development reported - Phase-II for Diabetic retinopathy in Hungary (SC) (EyeGene pipeline, September 2021)
- 28 Sep 2021 Phase-II clinical trials in Diabetic foot ulcer in South Korea (Topical) (EyeGene pipeline, September 2021)